Application of heme oxygenase 1 in the diagnosis of non-alcoholic fatty liver disease
10.3760/cma.j.issn.l007-3418.2019.04.010
- VernacularTitle:血红素氧合酶1在非酒精性脂肪性肝病诊断中的应用研究
- Author:
Xiwei YUAN
1
;
Dongdong LI
;
Lingdi LIU
;
Ying ZHANG
;
Wen ZHAO
;
Luyao CUI
;
Yang YANG
;
Yuemin NAN
Author Information
1. 河北医科大学第三医院中西医结合肝病科
- Keywords:
Diagnosis;
Non-alcoholic fatty liver disease;
Molecular marker;
Heme oxygenase-1
- From:
Chinese Journal of Hepatology
2019;27(4):291-297
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical value of plasma heme oxygenase l(HO-l)in the development of non-alcoholic fatty liver disease(NAFLD).Methods Patients with NAFLD were selected from the Physical examination center and the Department of Traditional and Western Medical Hepatology of Third Hospital of Hebei Medical University.A combination of ultrasound and liver elastography was used to screen NAFLD patients and healthy persons.General clinical characteristics,peripheral blood cell count and liver biochemical test results were collected synchronously,plasma samples were retained,and plasma HO-1 level was detected by enzyme-linked immunosorbent assay.SPSS21.0 statistical software was used for statistical analysis,multivariate logistic regression analyses was used to analyse the independent risk factors affecting the incidence and progression of NAFLD.The diagnostic efficacy of indicators related to development of NAFLD was assessed by the receiver operating characteristic curve(ROC).Results A total of 328 patients with NAFLD and 113 healthy controls were included.According to the liver biochemical results,the NAFLD group was divided into 148 patients with normal liver enzymes and 180 patients with abnormal liver enzymes.The level of HO-1 in the three groups was 9.09±2,19,14.38±2.63,17.00±3.30 ng/ml,and was increased respectively of healthy controls,patients with normal liver enzymes and patients with abnormal liver enzymes.Analyzing plasma HO-1 levels of components associated with metabolic disorders suggests that components without metabolic syndrome(9.83±3.21)
